AstraZeneca has today launched a programme aimed at tackling the burden of hypertension in Africa. Healthy Heart Africa is designed in consultation and collaboration with non-governmental and community based organisations, international organisations, health experts and governments to support local health systems by increasing awareness of the symptoms and risks of hypertension and offering education, screening, treatment and control. The programme will initially be launched in Kenya, with a view to expanding to other countries in the continent.
Cardiovascular disease is the leading cause of death among those aged over 45 in Africa. The continent has the highest prevalence of adults with hypertension, or high blood pressure, which puts patients at high risk of developing more serious cardiovascular conditions such as heart disease or stroke. Together with seven partners, AMPATH, AMREF Kenya, the Christian Health Association of Kenya, Jhpiego, Population Services Kenya, Mission for Essential Drugs and Supplies and Abt Associates, AstraZeneca will run five demonstration projects to test different ways of addressing the barriers currently preventing access to care for patients with high blood pressure.
AstraZeneca has initiated the programme to highlight its commitment to improving the health of patients in Africa, leveraging its knowledge of cardiovascular disease – one of its core therapy areas – to make a significant impact on what is becoming one of the continent’s major causes of mortality and morbidity. The programme also reinforces the company’s long-term growth ambition in the region. Healthy Heart Africa, the first programme of its kind, has three components:
- Education and awareness – increasing awareness of the risk factors associated with hypertension and how to prevent it, as well as prompting patients to access screening services.
- Provider training and treatment guidelines – supporting training for health and community care workers and developing guidelines with professional societies and the Kenyan Ministry of Health to ensure consistency in the level and quality of care.
- Access and affordability – improving access to hypertension treatment and ensuring a consistent supply of low priced, affordable medicines including calcium-channel blockers, angiotensin-converting enzyme (ACE) inhibitors and hydrochlorothiazide diuretics.
The demonstration projects will run for a period of 12-18 months and will test different models to determine the most effective methods of integrating hypertension care into existing health platforms, including USAID-supported HIV/AIDS care platforms, networks of private primary care providers and pharmacies and public and faith-based clinics. The projects will be carried out predominantly in urban and surrounding areas in the central and western counties of Kenya and will be independently evaluated. Those demonstrating the greatest impact will be taken forward and expanded across the country and, in the longer term, into other parts of Africa.
Mark Mallon, Executive Vice President, International at AstraZeneca, said: “Recognising a significant unmet medical need, we have been working closely with governments, health experts and community organisations to design a programme that can have a real and lasting impact on the identification, treatment and prevention of hypertension in Africa – one that offers education and care as well as access to affordable medicines. By taking a holistic approach to healthcare delivery, establishing strong working partnerships and securing local ownership through collaboration at all levels of the healthcare system, we will ensure that Healthy Heart Africa is sustainable over the long-term.”
Prof. Elijah Ogola, Kenya Vice-President (East), Pan African Society of Cardiology, said: “Cardiovascular disease is rapidly rising in Africa and hypertension is one of the main risk factors. In Kenya alone, over 40 per cent of adults have high blood pressure and it is vital that we address this growing problem early by increasing awareness, treatment and control rates. We welcome AstraZeneca’s Healthy Heart Africa programme, which has the potential to have a significant impact on the burden of cardiovascular disease across this continent.”
Hypertension is an often-overlooked non-communicable disease that puts patients at high risk of developing more serious cardiovascular conditions such as coronary heart disease and stroke. Africa has the highest prevalence of adults with hypertension at 46%, and a quarter of all premature deaths in Africa are attributable to the condition*. AstraZeneca’s ambition through the programme is to ensure that 10 million patients with high blood pressure are on treatments which control their condition by 2025, supporting the World Health Organisation’s (WHO’s) ‘25 by 25’ global monitoring framework for preventing and controlling non-communicable diseases. If achieved, this would address a quarter of the WHO’s hypertension target in Africa.
*World Health Organisation Global Status Report on non-communicable diseases 2010.http://www.who.int/nmh/publications/ncd_report_full_en.pdf.
About AstraZeneca’s Healthy Heart Africa partners
AMPATH (The Academic Model Providing Access to Healthcare) was established in 2001 as part of the Ministry of Health’s response to the HIV pandemic. With funding from USAID, AMPATH was able to rapidly scale up to become one of the largest and most comprehensive HIV programmes within the Ministry of Health. AMPATH represents a collaborative construct that is unique in Africa. It represents a North American consortium teamed with Moi University School of Medicine and Moi Teaching and Referral Hospital – with each member of the collaboration armed with a new sense of mission. That mission is for AMPATH to join with the Ministry of Health and new county governments to assist in creating comprehensive models of care that are responsive to the needs of the population. AMPATH continues to impact the community with innovative care interventions, research and training in the fields of HIV and non-communicable diseases and its response covers primary to tertiary care.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
Ref: 1. Official Press release of astrazeneca. 2. http://www.worldpharmanews.com/astrazeneca/2931-astrazeneca-launches-healthy-heart-africa-programme-to-address-hypertension-in-africa